{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:36:22Z","timestamp":1790825782631,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1A2C2009227"],"award-info":[{"award-number":["2020R1A2C2009227"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background and aim<\/jats:title><jats:p>The current cut-offs for fibrosis-4 (FIB-4) and non-alcoholic fatty liver disease fibrosis score (NFS) are suboptimal for screening because of low accuracy and high false-negative rates in average-risk populations. This study aimed to reappraisal the performance of FIB-4 and NFS in such average-risk populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a cross-sectional study, which retrospectively reviewed the magnetic resonance elastography (MRE) data of 8,522 subjects. Individuals with history of significant alcohol consumption and those with positive viral serologic markers were excluded. Finally, 6,215 average-risk individuals were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The area under the receiver operating characteristic curves (AUROCs) of FIB-4 for the diagnosis of advanced hepatic fibrosis was higher than that in the NFS especially in the metabolically healthy. The AUROCs of FIB-4 for in the average-risk population was also higher than that in the NFS (0.840 in FIB-4 vs. 0.798, <jats:italic>P<\/jats:italic> = 0.036). However, the sensitivity of FIB-4 and NFS was low (69.6 and 61.4%, respectively) in applying the current cut-off of FIB-4 [1.3 (2.0)] and NFS [-1.455 (0.12)]. At cut-off of FIB-4 at 1.0, sensitivity (90.2%), and negative predictive value (99.7%) were improved.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The diagnostic performance of FIB-4 was better than that of NFS for screening hepatic fibrosis in average-risk populations. It is recommended to use FIB-4 rather than NFS, when screening for hepatic fibrosis in general population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1024836","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T05:36:10Z","timestamp":1667453770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population"],"prefix":"10.3389","volume":"9","author":[{"given":"Huiyul","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen L.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonghyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Won","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Hee","family":"Nah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/hep.32228","article-title":"Global burden of NAFLD and chronic liver disease among adolescents and young adults.","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/apt.15673","article-title":"Modelling NAFLD disease burden in four Asian regions\u20142019\u22122030.","volume":"51","author":"Estes","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta\u2212analysis.","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000443344","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.","volume":"9","year":"2016","journal-title":"Obesity Facts."},{"key":"B6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2016.0049","article-title":"Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.","volume":"22","author":"Oh","year":"2016","journal-title":"Clin Mol Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/apt.15626","article-title":"Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check\u2212up clinic population.","volume":"51","author":"Kang","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e046529","DOI":"10.1136\/bmjopen-2020-046529","article-title":"Prevalence of liver fibrosis and associated risk factors in the Korean general population: a retrospective cross-sectional study.","volume":"11","author":"Nah","year":"2021","journal-title":"BMJ Open."},{"key":"B10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20132021 update.","volume":"75","author":"Panel","year":"2021","journal-title":"J Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population.","author":"Graupera","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease.","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD Fibrosis.","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity.","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/jcm11061474","article-title":"Selecting the target population for screening of hepatic fibrosis in primary care centers in Korea.","volume":"11","author":"Park","year":"2022","journal-title":"J Clin Med."},{"key":"B16","author":"Mittelstaedt","year":"1992","journal-title":"General ultrasound."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cgh.2007.06.012","article-title":"Assessment of hepatic fibrosis with magnetic resonance elastography.","volume":"5","author":"Yin","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants.","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/hep.28337","article-title":"MRE is superior to ARFI for the diagnosis of fibrosis in patients with biopsy-proven NAFLD: a prospective study.","volume":"63","author":"Cui","year":"2016","journal-title":"Hepatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"W20","DOI":"10.2214\/AJR.19.21267","article-title":"Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease.","volume":"214","author":"Furlan","year":"2020","journal-title":"Am J Roentgenol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.14309\/ctg.0000000000000157","article-title":"Multiparametric MR is a valuable modality for evaluating disease severity of nonalcoholic fatty liver disease.","volume":"11","author":"Lee","year":"2020","journal-title":"Clin Trans Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/ajg.2016.65","article-title":"Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study.","volume":"111","author":"Loomba","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.cgh.2020.12.016","article-title":"Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease.","volume":"20","author":"Imajo","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13577-022-00760-y","article-title":"FOSL2 deficiency delays nonalcoholic steatohepatitis progression by regulating LY6D-mediated NLRP3 activation.","volume":"2022","author":"Hu","year":"2022","journal-title":"Hum Cell."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01054-3","article-title":"Cardiomyocyte-specific knockout of ADAM17 ameliorates left ventricular remodeling and function in diabetic cardiomyopathy of mice.","volume":"7","author":"Xue","year":"2022","journal-title":"Signal Trans Target Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"8624","DOI":"10.7150\/thno.48561","article-title":"Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis.","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics."},{"key":"B27","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3390\/jcm11061474","article-title":"Selecting the target population for screening of hepatic fibrosis in primary care centers in Korea.","volume":"11","author":"Park","year":"2022","journal-title":"J Clin Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection.","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jhep.2019.12.025","article-title":"FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease.","volume":"73","author":"Shah","year":"2020","journal-title":"J Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1024836\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T05:36:15Z","timestamp":1667453775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1024836\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":30,"alternative-id":["10.3389\/fmed.2022.1024836"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1024836","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]},"article-number":"1024836"}}